For instance, the prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) have been popular targets in prostate cancer therapeutics as their expression is relatively restricted and markedly increased in patients with prostate cancer [9–12]. This evidence concerns the gene FOLH1 and prostate cancer.